Navigation Links
Worm studies shed light on human cancers
Date:4/21/2011

MADISON -- Research in the worm is shedding light on a protein associated with a number of different human cancers, and may point to a highly targeted way to treat them.

University of Wisconsin-Madison scientists were studying a worm protein called TFG-1, which is present in many cell types but whose exact role had never been understood. The scientists discovered that the protein controls key aspects of the movement, or secretion, of growth factors out of cells.

"TFG-1 has never been implicated in the secretory process before," says Dr. Anjon Audhya, an assistant professor of biomolecular chemistry in the School of Medicine and Public Health. "It turns out that humans carry a very similar protein, and we think it plays the same role in humans as in worms."

Reviewing the scientific literature, the researchers found that the gene encoding TFG in humans is fused to at least three other genes implicated in anaplastic large cell lymphoma, papillary thyroid carcinoma and extraskeletal chondrosarcoma. The fusions occur when two broken or rearranged pieces of DNA combine to form a "chimeric" gene with completely distinct properties.

Audhya's studies of TFG-1 in the worm led him to develop a model that explains how TFG fusions may stimulate cancer in humans. As reported in the current issue of Nature Cell Biology (Advanced Online Publication), he proposes that abnormal levels of growth factor secretion may produce a rich micro-environment that helps tumors form and thrive. "We think certain properties of TFG lead it to be a very effective precursor oncogene," he says.

Normally, a growth factor primed to leave a cell is encompassed by a sac, or vesicle, and then transported from one structure inside the cell to anotherendoplasmic reticulum (ER) to Golgibefore it leaves the cell and discharges into the extracellular space.

Through their genetic studies, the Wisconsin researchers found that TFG-1 in the worm controls vesicle formation and secretion out of the ER.

"We found TFG-1 lies at the interface between the ER and the Golgi, in a scaffolding structure called the ER exit site, where it regulates the formation of vesicles carrying their critical cargo," Audhya says.

The research revealed the precise location where TFG-1 does its work and the mechanism by which it spurs unchecked activity.

The scientists demonstrated that human TFG also functions at ER exit sites, which contain a characterized scaffolding protein called Sec16, and likely regulates secretion of multiple cargoes out of cells.

"In the case of one fusion gene, TFG-NTRK-1, the concentrated non-stop activity of NTRK-1 at ER exit sites may cause the first steps that can transform a normal cell into a cancer cell," Audhya says.

The TFG fusions offer a direct target for future "designer" therapies.

"If you identified patients who have fusion genes that express chimeric proteins, you could create a drug that affects only those proteins," he says, adding that TFG fusions leading to chimeric proteins do not exist in healthy people.

Excited about the possibility that their basic science investigations may be applied to several areas of clinical medicine, the researchers have also begun studying TFG as it relates to B-cell development and the secretion of antibodies.


'/>"/>

Contact: Dian Land
dj.land@hosp.wisc.edu
608-261-1034
University of Wisconsin-Madison
Source:Eurekalert

Related medicine news :

1. UC studies show marijuana has therapeutic value, reports to legislature
2. Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies
3. Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis
4. COPPERTONE(R) Solar Research Center Unveils Studies on Efficacy of Topical Antioxidants in Sunscreens at 2010 Annual Meeting of The American Academy of Dermatology
5. Promega - TOP srl Agreement Enables Live Animal Imaging for Cancer Studies
6. Most Drug Studies Dont Help Docs Pick Best Treatment
7. Gays, Lesbians Excluded From Some Medical Studies
8. Studies Show Significant Increases of C. Difficile Infections (CDI)
9. Studies examine Third Eye Retroscope during colonoscopy
10. Statement of Ralph B. Everett, President and CEO, Joint Center for Political and Economic Studies, on House Passage of Health Reform Legislation
11. New studies on surgical options in inherited breast cancer show drastic treatment is not always best
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... Viejo, CA (PRWEB) , ... February 18, 2017 ... ... animating paragraph presets. Use Pixel Film Studios ’ ProParagraph Fashion Volume ... descriptions, and so many other applications. Users can pick and choose from ...
(Date:2/17/2017)... ... 2017 , ... While EHR data has revolutionized the nursing ... workstation designed to reduce nursing fatigue while enhancing productivity. Based on field experience ... lightweight, highly mobile, multi-functional alternative to the limitations of handheld computing. , Nurses ...
(Date:2/17/2017)... ... February 17, 2017 , ... For the first ... solution to the exhibit floor for the 2017 HIMSS Conference & Exhibition ... Feb. 19–23, 2017, more than 40,000 healthcare industry professionals are expected at the ...
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective Action & Preventive Action ... Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/capamd ... preventive action (PA)? , The methods share techniques and tools but they are ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... by fall 2017 season , Trinity Health and the U.S. Soccer Foundation announced ... Success program in underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , February 17, 2017 According to ... Particle Counters, Liquid Particle Counters), Application (Cleanroom Monitoring, Contamination Monitoring of ... to 2021" published by MarketsandMarkets, the market is expected to reach ... at a CAGR of 3.7% from 2016 to 2021. ... ...
(Date:2/17/2017)... DUBLIN , Feb. 17, 2017  Perrigo Company plc (NYSE, ... the U.S. Food and Drug Administration for hydrocodone bitartrate and ... mL. Hydrocodone bitartrate and homatropine methylbromide oral ... for the symptomatic relief of cough in adults and children ... 12 months ending January 2017 were approximately $16 million.   ...
(Date:2/17/2017)... YORK , Feb. 17, 2017   Risperdal ... side effects allegedly associated with use of the atypical ... Philadelphia Court of Common Pleas, where ... mass tort program. According to a notice posted on ... to convene a meeting on March 9, 2017 at ...
Breaking Medicine Technology: